Myeloproliferative Neoplasms News

ASH announced this year’s recipients of its honorific awards.

Ivosidenib and venetoclax with or without azacitidine appeared safe and effective for the treatment of IDH1-positive myeloid malignancies, according to phase 1B/phase 2 study results presented during the ASCO20 Virtual Scientific Program.

African Americans have been routinely underrepresented in clinical trials supporting FDA approval of drugs for all types of cancer, according to results of a retrospective study published in Annals of Internal Medicine.

ASH Research Collaborative’s Data Hub launched an international data registry to help inform care for individuals with blood cancers and COVID-19.

The FDA granted orphan drug designation to SEL120 for the treatment of acute myeloid leukemia, according to the agent’s manufacturer.

Patterns of microbiota disruption, marked by loss of intestinal diversity and single taxa domination, appeared similar among a cohort of patients undergoing allogeneic hematopoietic stem cell transplantation across various centers and geographic areas, according to findings published in The New England Journal of Medicine.

Evaluation by a multidisciplinary team clinic prior to hematopoietic stem cell transplantation appeared to reduce transplant-related morbidity and mortality among older adults with blood cancers, according to results of a prospective survey-based study published in Blood Advances.

Eileen Smith, MD, has been appointed chair of the department of hematology and hematopoietic cell transplantation at City of Hope.

Gabriela S. Hobbs, MD, and Oluwatoyosi Adefunke Onwuemene, MD, MS, will participate in the American Society of Hematology-Harold Amos Medical Faculty Development Program.

The FDA granted breakthrough therapy designation to APR-246 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation, according to a company-issued press release.